Jolien Robijns1, Joy Lodewijckx1, Rene-Jean Bensadoun2, Jeroen Mebis1,3,4. 1. Faculty of Medicine and Life Sciences, Limburg Clinical Research Center, Hasselt University, Hasselt, Belgium. 2. Radiation Oncology, Centre de Haute Energie, Nice, France. 3. Limburg Oncology Center, Jessa Hospital, Hasselt, Belgium. 4. Division of Medical Oncology, Jessa Hospital, Hasselt, Belgium.
Abstract
Objective: A narrative review of the available scientific evidence to identify the current proposals relating the use of photobiomodulation (PBM) to treat acute radiodermatitis (ARD), to guide future research. Background data: A devastating side effect of radiotherapy (RT) is ARD, defined as an inflammatory skin reaction induced by RT. Currently, there is still no standard of care for ARD. PBM is a non-invasive light therapy that is a growing modality in the field of supportive cancer care. There is a need for identifying the therapeutic irradiation windows in this field, based on the available literature. Methods: An electronic search of original articles in the PubMed database was performed with the following keywords: "photobiomodulation therapy," "low-level light therapy," "low-level laser therapy," "acute radiodermatitis," and "radiotherapy" until December 2019. Randomized controlled trials, prospective non-randomized, case report, cohort, cross-over, and retrospective studies were selected for this review. Results: Nine clinical trials that investigated the use of photobiomodulation therapy (PBMT) in ARD were available for evaluation. Results demonstrate that PBMT could significantly reduce the severity of ARD and the accompanying discomfort and pain in patients with cancer. Conclusions: Based on the available evidence of the narrative review, PBM might be an effective therapy for the prevention and management of ARD in patients with cancer. More research is needed to confirm this finding.
Objective: A narrative review of the available scientific evidence to identify the current proposals relating the use of photobiomodulation (PBM) to treat acute radiodermatitis (ARD), to guide future research. Background data: A devastating side effect of radiotherapy (RT) is ARD, defined as an inflammatory skin reaction induced by RT. Currently, there is still no standard of care for ARD. PBM is a non-invasive light therapy that is a growing modality in the field of supportive cancer care. There is a need for identifying the therapeutic irradiation windows in this field, based on the available literature. Methods: An electronic search of original articles in the PubMed database was performed with the following keywords: "photobiomodulation therapy," "low-level light therapy," "low-level laser therapy," "acute radiodermatitis," and "radiotherapy" until December 2019. Randomized controlled trials, prospective non-randomized, case report, cohort, cross-over, and retrospective studies were selected for this review. Results: Nine clinical trials that investigated the use of photobiomodulation therapy (PBMT) in ARD were available for evaluation. Results demonstrate that PBMT could significantly reduce the severity of ARD and the accompanying discomfort and pain in patients with cancer. Conclusions: Based on the available evidence of the narrative review, PBM might be an effective therapy for the prevention and management of ARD in patients with cancer. More research is needed to confirm this finding.
Authors: Jolien Robijns; Raj G Nair; Joy Lodewijckx; Praveen Arany; Andrei Barasch; Jan M Bjordal; Paolo Bossi; Anne Chilles; Patricia M Corby; Joel B Epstein; Sharon Elad; Reza Fekrazad; Eduardo Rodrigues Fregnani; Marie-Thérèse Genot; Ana M C Ibarra; Michael R Hamblin; Vladimir Heiskanen; Ken Hu; Jean Klastersky; Rajesh Lalla; Sofia Latifian; Arun Maiya; Jeroen Mebis; Cesar A Migliorati; Dan M J Milstein; Barbara Murphy; Judith E Raber-Durlacher; Hendrik J Roseboom; Stephen Sonis; Nathaniel Treister; Yehuda Zadik; René-Jean Bensadoun Journal: Front Oncol Date: 2022-08-30 Impact factor: 5.738